Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...
The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...
The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback